Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Guangji Pharma to Raise $87 Million via Private Placement to Controlling Shareholder

Fineline Cube Feb 12, 2026
Company Deals

uBriGene Biosciences Partners with BriSTAR Immunotech on Universal STAR-T Cell Therapy CDMO

Fineline Cube Feb 12, 2026
Company Deals

Newsoara BioPharma Expands Global Rights to vTv’s PDE4 Inhibitor HPP737 in $135 Million Deal

Fineline Cube Feb 11, 2026
Company Deals Medical Device

Siemens Healthineers Partners with Northwestern Medicine to Advance Precision Cancer Care

Fineline Cube Feb 11, 2026
Company Deals

Cascade Pharma Raises $72 Million to Advance MASH and Obesity Pipeline to Phase III

Fineline Cube Feb 11, 2026
Policy / Regulatory

FDA Cracks Down on Compounded GLP-1 APIs; Novo Nordisk Sues Hims & Hers for Patent Infringement

Fineline Cube Feb 11, 2026
Company Drug

Eli Lilly’s Jaypirca Wins NMPA Approval for CLL/SLL Post-BTK Inhibitor Therapy

Fineline Cube Feb 12, 2026
Company Drug

Hengrui’s Trastuzumab Rezetecan Wins Eighth BTD for First-Line HER2+ NSCLC in China

Fineline Cube Feb 12, 2026
Company Drug

J&J Submits sNDA to FDA for Caplyta to Prevent Schizophrenia Relapse

Fineline Cube Jul 9, 2025

US giant Johnson & Johnson (J&J, NYSE: JNJ) announced the submission of a supplemental New...

Company Drug

Novartis’ Coartem Baby Approved by Swissmedic for Newborns and Young Infants

Fineline Cube Jul 9, 2025

Swiss pharmaceutical giant Novartis (NYSE: NVS) announced that it has received marketing approval from Swissmedic...

Company Drug

Jiangsu Hengrui Gains NMPA Clinical Clearance for HRS-9821 in COPD Treatment

Fineline Cube Jul 9, 2025

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that it has received clinical clearance...

Policy / Regulatory

NMPA Updates Review Procedures for Conditional Drug Marketing Approval Applications

Fineline Cube Jul 9, 2025

The National Medical Products Administration (NMPA) this week released a revised draft proposal for the...

Company Medical Device

Boston Scientific’s FARAPULSE Gains FDA Approval for Expanded Use in Persistent Atrial Fibrillation

Fineline Cube Jul 9, 2025

US-based Boston Scientific Corporation (NYSE: BSX) announced that it has received US FDA approval for...

Company Drug

HutchMed Announces First Commercial Shipments of Tazverik Across China

Fineline Cube Jul 9, 2025

China-based HutchMed (NASDAQ: HCM, HKG: 0013) announced the first commercial shipments of Tazverik (tazemetostat) across...

Company Deals Medical Device

Shenzhen Concemed Medtech Secures Hundreds of Millions in Series A+ Funding for Endoscopy Expansion

Fineline Cube Jul 8, 2025

Shenzhen Concemed Medical Technology Co., Ltd., a China-based endoscope specialist, has reportedly secured “hundreds of...

Company Drug

RemeGen Submits New Indication Application for Disitamab Vedotin in Urothelial Carcinoma

Fineline Cube Jul 8, 2025

RemeGen Ltd (HKG: 9995) announced that the National Medical Products Administration (NMPA) in China has...

Company Drug

Grand Pharma’s SIR-Spheres Y-90 Gets FDA Accelerated Approval for Unresectable HCC

Fineline Cube Jul 8, 2025

China-based Grand Pharmaceutical Group Limited (HKG: 0512) announced that SIR-Spheres Y-90 resin microspheres (SIR-Spheres), a...

Company Drug

Boehringer Ingelheim Starts Phase III THULITE Study for BI 1815368 in Diabetic Macular Edema

Fineline Cube Jul 8, 2025

German pharmaceutical major Boehringer Ingelheim announced the initiation of the Phase III THULITE study to...

Company Deals

GSK Completes Acquisition of Boston Pharma’s BP Asset IX for Efimosfermin Alpha

Fineline Cube Jul 8, 2025

UK-based GlaxoSmithKline (GSK; NYSE: GSK) announced the completion of its acquisition of BP Asset IX, a...

Company Deals

Qilu Pharmaceutical Partners with Sagent Pharmaceuticals to Expand US Market Presence

Fineline Cube Jul 8, 2025

China-based Qilu Pharmaceutical Co., Ltd. this week announced a strategic partnership with US-headquartered Sagent Pharmaceuticals....

Policy / Regulatory

NMPA Releases 93rd Batch of Reference Drugs for Generic Quality Consistency Evaluation

Fineline Cube Jul 8, 2025

The National Medical Products Administration (NMPA) has released the 93rd batch of reference drugs for...

Company Deals Drug

Roche’s Chugai Pharmaceutical Partners with Gero to Develop Therapies for Age-Related Diseases

Fineline Cube Jul 8, 2025

Roche’s Japan-based subsidiary Chugai Pharmaceutical Co., Ltd. (TYO: 4519) announced this week a joint research...

Company Deals

CStone Pharmaceuticals Licenses Cejemly to Istituto Gentili for 23 Countries in Europe and the UK

Fineline Cube Jul 8, 2025

China-based CStone Pharmaceuticals (HKG: 2616) announced a licensing agreement with Istituto Gentili S.R.L., granting the...

Company Drug

Jiangsu CTTQ’s TQB2102 Receives Breakthrough Therapy Designation for HER2+ Breast Cancer

Fineline Cube Jul 8, 2025

Subsidiary of China based Sino Biopharmaceutical Ltd (HKG: 1177) Jiangsu Chia Tai Tianqing Pharmaceutical Co.,...

Company Drug

Wepon Medical Receives NMPA Clinical Approval for WP107 in Generalized Myasthenia Gravis

Fineline Cube Jul 8, 2025

Wepon Medical Holding Group Co., Ltd. (SHE: 002082) announced that it has received clinical approval...

Policy / Regulatory

China’s CDE Announces 95th Batch of Reference Preparations for Public Comment

Fineline Cube Jul 7, 2025

China’s Center for Drug Evaluation (CDE) has released the 95th batch of reference preparations for...

Policy / Regulatory

China Ministry of Finance Restricts EU-Imported Medical Devices in Government Procurement Over RMB45 Million

Fineline Cube Jul 7, 2025

China’s Ministry of Finance (MoF) has issued the “Notice on Implementing Relevant Measures for EU-Imported...

Company Drug

SCG Cell Therapy Obtains NMPA Approval for SCG101V in Chronic HBV Study

Fineline Cube Jul 7, 2025

China’s Center for Drug Evaluation of the National Medical Products Administration (NMPA) has approved SCG...

Posts pagination

1 … 88 89 90 … 623

Recent updates

  • PANACRO Pharma Files Hong Kong IPO to Expand Digital Clinical Research Platform
  • Eli Lilly’s Jaypirca Wins NMPA Approval for CLL/SLL Post-BTK Inhibitor Therapy
  • Hengrui’s Trastuzumab Rezetecan Wins Eighth BTD for First-Line HER2+ NSCLC in China
  • Eli Lilly’s Mounjaro Wins NMPA Monotherapy Approval for Type 2 Diabetes in China
  • Guangji Pharma to Raise $87 Million via Private Placement to Controlling Shareholder
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Others

PANACRO Pharma Files Hong Kong IPO to Expand Digital Clinical Research Platform

Company Drug

Eli Lilly’s Jaypirca Wins NMPA Approval for CLL/SLL Post-BTK Inhibitor Therapy

Company Drug

Hengrui’s Trastuzumab Rezetecan Wins Eighth BTD for First-Line HER2+ NSCLC in China

Company Drug

Eli Lilly’s Mounjaro Wins NMPA Monotherapy Approval for Type 2 Diabetes in China

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.